

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

**ANNOUNCEMENT ON ESTIMATED PROFIT DECREASE FOR THE
SIX MONTHS ENDED 30 JUNE 2021**

This announcement is made by Lansen Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries shall be referred to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XI VA Insider Information Provisions (as defined in the Listing Rules) of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

The Company wishes to inform the shareholders of the Company and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021:

1. the Group’s revenue is expected to record a moderate decrease as compared with that of the same period last year;
2. the Group’s operating profit is expected to record a significant decrease as compared with that of the same period last year; and
3. the Group’s net profit is expected to record a significant decrease as compared with that of the same period last year.

The decrease in the Group’s revenue was primarily attributable to the decrease in sales volume of the Group’s core products Pafulin and Sicorten as compared with those in the same period last year. The Group has noticed the decrease in sales volume and is currently adjusting the sales strategies.

The decrease in the Group’s operating profit was primarily attributable to the aforementioned decrease in revenue, which resulted in a decrease of corresponding gross profit.

The decrease in the Group's net profit was primarily attributable to a one-off net income arising from the reclassification of the interest in Starry as financial assets at fair value through profit or loss ("FVTPL") in the same period last year and no such one-off net income was recorded in the current period. In addition, an unrealised loss from the changes in value of the financial assets at FVTPL was recorded in the current period while an unrealised gain was recorded in the same period last year.

The information contained in this announcement is only a preliminary estimation by the management of the Group based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 and the information currently available, which have not been reviewed or audited by the auditors of the Company nor approved by the audit committee of the Company. Therefore, the actual results of the Group for the six months ended 30 June 2021 may be different from the information contained herein. The interim results of the Group for the six months ended 30 June 2021 is expected to be announced by the end of August 2021.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Hong Kong, 29 July 2021

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Fritz Heinrich Horlacher and Mr. Yeung Tak Bun, Allen.